Oaktree Acquisition Corp. III Life Sciences
Status: Pre-Deal
U=S+W/5
W=S@11.50
| IPO Proceeds, $M | $175.00M |
|---|---|
| IPO Date | Oct 24, 2024 |
| CEO | Zaid Pardesi |
| Left Lead | Jefferies |
| IPO Cash in Trust | 100.0% |
| SPAC Tenor | 24 months |
| IPO Sector |
Healthcare
North American, British or European companies in the biopharmaceutical, medical devices, diagnostics, and specialized healthcare services sectors |
| IPO Geography | Global |
| Target Company | TBD |
| Deal Announced | TBD |
| Deal Size, $M | TBD |
| Deal Sector | TBD |
| Deal Geography | TBD |
| SEC Filings | www.sec.gov |
| Approval Vote | TBD |
| Amendment Vote | TBD |
OACC
OACCU
OACCW
| Price | |
|---|---|
| Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in for more on Oaktree Acquisition Corp. III Life Sciences:
- Structure and cap table
- 7 directors & officers
- 3 filings and events
- 3 underwriters
Structure
Sign in to view structure, cap table, and calendar of events.
Team
| Name | Age | Title |
|---|---|---|
| John Frank | 68 | Chairman and Director |
| Zaid Pardesi | 41 | Chief Executive Officer |
| Aman Kumar | 44 | Director |
| Mathew Pendo | 61 | Chief Operating Officer |
| Courtney Conigliaro | 43 | Chief Financial Officer |
| Paul Meister | 71 | Director |
| Alvin Shih | 47 | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
Filings
| Oct 4, 2024 | Initial S-1 |
| Oct 23, 2024 |
PR announcing pricing of $175mm IPO
Sign In to view filing content. |
| Oct 24, 2024 | 424B4 IPO Prospectus |